175 related articles for article (PubMed ID: 17344303)
1. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.
Finnegan CM; Rawat SS; Cho EH; Guiffre DL; Lockett S; Merrill AH; Blumenthal R
J Virol; 2007 May; 81(10):5294-304. PubMed ID: 17344303
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
3. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
Xiao X; Kinter A; Broder CC; Dimitrov DS
Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381
[TBL] [Abstract][Full Text] [Related]
4. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
5. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry.
Baleux F; Loureiro-Morais L; Hersant Y; Clayette P; Arenzana-Seisdedos F; Bonnaffé D; Lortat-Jacob H
Nat Chem Biol; 2009 Oct; 5(10):743-8. PubMed ID: 19734912
[TBL] [Abstract][Full Text] [Related]
6. Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1.
Kozak SL; Kuhmann SE; Platt EJ; Kabat D
J Biol Chem; 1999 Aug; 274(33):23499-507. PubMed ID: 10438529
[TBL] [Abstract][Full Text] [Related]
7. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
8. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2001 Nov; 75(22):11096-105. PubMed ID: 11602749
[TBL] [Abstract][Full Text] [Related]
9. HIV coreceptors: from discovery and designation to new paradigms and promise.
Alkhatib G; Berger EA
Eur J Med Res; 2007 Oct; 12(9):375-84. PubMed ID: 17933717
[TBL] [Abstract][Full Text] [Related]
10. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
11. Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes.
Barrero-Villar M; Cabrero JR; Gordón-Alonso M; Barroso-González J; Alvarez-Losada S; Muñoz-Fernández MA; Sánchez-Madrid F; Valenzuela-Fernández A
J Cell Sci; 2009 Jan; 122(Pt 1):103-13. PubMed ID: 19066282
[TBL] [Abstract][Full Text] [Related]
12. A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti- HIV-1 activity independently of coreceptor usage.
Connell BJ; Baleux F; Coic YM; Clayette P; Bonnaffé D; Lortat-Jacob H
Chem Biol; 2012 Jan; 19(1):131-9. PubMed ID: 22284360
[TBL] [Abstract][Full Text] [Related]
13. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
Agrawal L; Vanhorn-Ali Z; Alkhatib G
J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
[TBL] [Abstract][Full Text] [Related]
14. Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.
Dobrowsky TM; Zhou Y; Sun SX; Siliciano RF; Wirtz D
J Virol; 2008 Jul; 82(14):7022-33. PubMed ID: 18480458
[TBL] [Abstract][Full Text] [Related]
15. New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives.
Kanizsai S; Ongrádi J; Aradi J; Nagy K
Pathol Oncol Res; 2016 Jul; 22(3):617-23. PubMed ID: 26860867
[TBL] [Abstract][Full Text] [Related]
16. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
Mori T; Boyd MR
Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
18. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
19. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
20. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
